Biotech Startups

N2TP builds autonomous AI systems with formal mathematical verification for life science R&D, aiming to make AI-driven hypotheses and experiments reproducible and trustworthy. Its platform powers applications including SmartDoseAI for model-informed precision dosing of narrow-therapeutic-window drugs and the LynxDetect programmable biosensor for point-of-care diagnostics.

1 investor

n6 is a genomics technology company that develops methods and tools for molecular R&D and genomics research. The company serves researchers and genomics labs.

1 investor

Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.

1 investor

Nàdarra Ventures is a Canadian venture capital fund investing in early-stage companies developing sustainable solutions in agriculture, food, and materials through biotechnology and science-driven innovation.

1 investor

NADMED offers laboratory kits and analytical services for quantifying NAD and glutathione metabolites in research and diagnostic applications. The company provides CE-marked diagnostic kits, research-use-only kits, and custom quantification services for researchers and labs studying redox metabolism.

1 investor

Naegis Pharmaceuticals is a drug discovery and development company creating first-in-class small-molecule treatments for serious ophthalmic and inflammatory diseases. Its work targets inflammatory mechanisms, including leukotriene pathways, to develop new therapies for eye diseases.

1 investor

Nanil Therapeutics develops AI-native discovery platforms for CNS-targeting therapeutic modalities, focusing on RNA-based approaches for neurodegenerative diseases like tauopathies and Alzheimer's. The company integrates quantum computing, generative AI, and molecular modeling to design and optimize mRNA therapeutics and identify blood-brain barrier-penetrant biologics.

1 investor

NanoBio Designs develops nanotechnology-based assays and detection devices that use microparticle pairing to visibly identify target DNA sequences and genetic markers in grain samples such as soybeans. The company serves the agriculture and grain-processing industry, with operations in Indiana and Iowa.

1 investor

NanoCarry is developing a proprietary drug-delivery technology platform designed to move therapeutic antibodies across the blood-brain barrier for the treatment of brain cancers and central nervous system diseases. The platform uses a "Plug & Play" approach aimed at substantially increasing the brain delivery of injected antibody doses.

1 investor

NanoDx develops point-of-care diagnostic devices using nanowire biosensor technology to deliver rapid test results at patient locations, targeting unmet clinical needs globally.

1 investor

NANOEGG is a pharmaceutical and cosmetics development company that conducts drug research and development, produces non-pharmaceutical health products and cosmetics, and sells pharmaceutical bases and cosmetic raw materials. The company serves pharmaceutical manufacturers, cosmetics brands, and health product developers in Japan.

1 investor

Nanoflexion is a medtech spin-off developing an electrospun nanofiber surgical patch that acts as a biodegradable, biocompatible barrier to prevent anastomotic leakage and postoperative adhesions after colorectal and gastrointestinal surgery. The patch is applied during surgery without extra tools and can serve as a local drug delivery system, targeting surgical care in Europe.

1 investor

US-based vertically integrated biologics and disc replacement manufacturer, acquired by KIC in 2018.

1 investor

NanoGhost develops a drug targeting platform called Nano-Ghosts (NGs), nanovesicles made from the cell membrane of mesenchymal stem cells that target cancer and inflammation sites and can carry various therapeutic loads. The biotech company's technology originates from research at the Technion – Israel Institute of Technology.

1 investor

NanoGrow Biotech develops biological therapies based on a single-domain antibody (nanobody) platform, combined with various formulations such as topical, inhaled, injectable, and oral delivery. Its targeted therapies address conditions including psoriasis, asthma, inflammatory bowel disease, and melanoma.

1 investor

NanoGuard Technologies develops sterilization technologies for medical applications.

1 investor

NanoInGreen uses microbial fermentation with a platform of over 150 microorganism strains as biofactories to produce bioavailable, GRAS-status, GMO-free ingredients for the food industry, such as a natural food preservative and a highly absorbable iron mineral. It serves food companies looking to enhance formulations, replace existing ingredients, or develop new nutritional products.

1 investor

NanoJump develops portable technology for in-field extraction and purification of DNA/RNA, aiming to move genetic material extraction out of centralized labs. Its solutions support genome-based applications in disease prevention, precision medicine, and agricultural livestock productivity.

1 investor

NanoMedical Systems develops subcutaneous implantable drug-delivery devices built on its nStrada nanofluidics platform, which uses arrays of precision nanochannels to provide long-term, constant release of small molecules, peptides, and proteins for chronic therapies. The platform, manufactured with semiconductor methods, offers passive, refillable, and remotely controlled delivery systems for pharmaceutical and biologic drug delivery.

1 investor

1 investor

Nanopath is developing a molecular diagnostic platform designed for point-of-care disease diagnosis, with a focus on women's health. The company works to commercialize novel diagnostic technologies aimed at improving human health.

1 investor

Oxford Nanopore offers educational programs and tools to make DNA sequencing accessible to students and educators from high school through undergraduate levels. The company works with institutions and scientific educators to integrate nanopore sequencing technology into classroom settings and address the world's pressing challenges.

1 investor

NanoProX develops bismuth sulfide (Bi₂S₃) nanoparticles administered intravenously before radiotherapy to selectively accumulate in tumors and amplify local radiation dose, aiming to increase tumor cell elimination per session without new equipment. The company targets oncology treatment and works with research institutions and clinical centers on preclinical and clinical translation.

1 investor

Nanoptima develops drug delivery technologies for ophthalmic applications, focusing on biomaterial-based solutions for retinal and eye diseases. The company draws on deep pharma and biotech expertise to advance formulation science and delivery mechanisms for pharmaceutical treatments.

1 investor